Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.70 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 5/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485182 | 0.87 | NR1I2 (0.62) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL8152681 | 0.82 | NR1I2 (1.00) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL8157437 | 0.81 | CACNA1B (0.84) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL3486170 | 0.78 | NR1I2 (0.62) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL8157762 | 0.75 | NR1I2 (1.00) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL8156552 | 0.72 | CACNA1B (1.00) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL7681815 | 0.71 | CCR2 (0.55) | NR1I2CACNA1BCCR2CCR9 | |
| SCHEMBL8150584 | 0.71 | NR1I2 (0.80) | NR1I2CACNA1BNPC1GAA | |
| SCHEMBL8143702 | 0.71 | CACNA1B (0.83) | NR1I2CACNA1BNPC1GAAKDM4E | |
| SCHEMBL8150102 | 0.71 | NR1I2 (0.81) | NR1I2CACNA1BNPC1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME CORP. | 2010-04-08 | — | — | US | disclosed |
| WO-2008133867-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087446-A1 | 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, CACNA1S, TRPV2 | NR1I2 1761/4885CACNA1B 13/4885NPC1 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.